Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by t
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial
06:55am, Monday, 25'th Mar 2024
Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
06:45am, Saturday, 23'rd Mar 2024
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
12:36pm, Thursday, 21'st Mar 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
01:16pm, Wednesday, 20'th Mar 2024
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
07:00am, Tuesday, 05'th Mar 2024
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
07:00am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Biotech Stocks to Buy and Hold for the Next 10 Years
08:50am, Monday, 26'th Feb 2024
CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
11:41am, Wednesday, 21'st Feb 2024
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Tuesday, 20'th Feb 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.28 per share a year ago.
Why Axsome (AXSM) Might Surprise This Earnings Season
10:01am, Thursday, 15'th Feb 2024
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 13'th Feb 2024
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Stocks That Could Double Your Money in 5 Years
07:45am, Thursday, 08'th Feb 2024
Shopify and Axsome Therapeutics have crushed the market in the past five years. Thanks to a recent strategic move, Shopify's top and bottom lines should improve.
5 medical stocks growing earnings by triple digits
10:46am, Tuesday, 06'th Feb 2024
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Thursday, 25'th Jan 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
